Lexaria Bioscience Corp. Files Material Definitive Agreement

TL;DR

Lexaria Bioscience Corp. just signed a big deal, filing an 8-K on Dec 16th.

AI Summary

On December 16, 2024, Lexaria Bioscience Corp. entered into a material definitive agreement. The company, incorporated in Nevada with its principal executive offices in Kelowna, BC, Canada, filed this 8-K report on December 18, 2024.

Why It Matters

This filing indicates a significant new contract or partnership for Lexaria Bioscience Corp., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, making the company's future performance uncertain until more details are disclosed.

Key Players & Entities

• Lexaria Bioscience Corp. (company) — Registrant
• December 16, 2024 (date) — Date of earliest event reported
• December 18, 2024 (date) — Filing date
• Nevada (jurisdiction) — State of incorporation
• Kelowna, BC Canada (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
• $5.1 million — ate costs associated with the PA is ~AUD$5.1 million with certain initial start-up work asso
• $414,600 — ated with GLP-1-H24-4 (approximately AUD$414,600); and Payment of 15% of the total pass
• $347,800 — ated with GLP-1-H24-4 (approximately AUD$347,800); With such amounts being reduced by t

Filing Documents

• lxrp_8k.htm (8-K) — 25KB
• 0001640334-24-001908.txt ( ) — 162KB
• lxrp-20241216.xsd (EX-101.SCH) — 6KB
• lxrp-20241216_lab.xml (EX-101.LAB) — 16KB
• lxrp-20241216_cal.xml (EX-101.CAL) — 1KB
• lxrp-20241216_pre.xml (EX-101.PRE) — 12KB
• lxrp-20241216_def.xml (EX-101.DEF) — 4KB
• lxrp_8k_htm.xml (XML) — 5KB

0 Entry into a Material Definitive Agreement

Item 1.0 Entry into a Material Definitive Agreement Lexaria Bioscience Corp. via its wholly owned subsidiary, Lexaria (AU) Pty Ltd (" Lexaria AU ") has finalized the terms of its Project Agreement (the " PA ") with Novotech (Australia) Pty Limited (" Novotech ") and the associated project budget for the purposes of Novotech acting as Lexaria AU's clinical research organization (" CRO ") for its Australian clinical study "DehydraTECH Cannabidiol alone and in combination with glucagon-like peptide 1 agonists in pre- and Type II Diabetes" (" GLP-1-H24-4 "). The effective date of the PA is December 2, 2024. Pursuant to the terms and conditions of the Master Services Agreement (the " MSA ") and the associated PA, Lexaria AU has the ability to terminate the PA with or without cause upon 90 days' notice. The aggregate costs associated with the PA is ~AUD$5.1 million with certain initial start-up work associated with the PA having been completed under a Start-Up Agreement (the " SUA "). Upon signing the PA, Lexaria (AU) is responsible for: Payment of 15% of direct costs associated with GLP-1-H24-4 (approximately AUD$414,600); and Payment of 15% of the total pass through costs associated with GLP-1-H24-4 (approximately AUD$347,800); With such amounts being reduced by the fees that Lexaria AU paid to Novotech for the services provided under the SUA. The description of the PA with Novotech is qualified in its entirety by the agreement that will be filed as an exhibit to the Company's quarterly 10-Q Periodic Report. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Richard Christopher CEO, Principal Executive Officer Date: December 18, 2024 3